Our visionary leaders take bold actions to push possibilities

leadership team

A dedication to do better for patients. A bold drive for scientific and technological innovation. Our executive leadership team continues to inspire and initiate transformation while empowering others to do the same.

Board of directors

President and Chief Executive Officer

Ms. Barrett is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies.


Dr. Belldegrun is the Chairman of UroGen Pharma and has served as our Chair since December 2012. He has built a distinguished career as a visionary surgeon, scientist, and life sciences entrepreneur.

Board Member

Ms. Butitta is a seasoned financial and operational executive with more than 25 years of leadership experience in both the biotechnology and high-technology industries. She has served as a director for UroGen since October 2017.

Board Member

Dr. Cohen is a former academic clinician with many years of experience advising pharmaceutical and life sciences companies. Dr. Cohen has served as a director for UroGen since May 2017.

Board Member

Dr. Holden has a long and decorated career as a practicing urologist, research pioneer in prostate and urologic cancers, and an academic. He has served as a director for UroGen since December 2015.

Board Member

Mr. Robinson has excelled in building and leading organizations from inception to commercial success throughout his 30+ years of experience in the biopharmaceutical industry. Mr. Robinson currently serves as the President, Chief Executive Officer and a member of the Board of Directors for A2 Biotherapeutics. Previously he served as a member of the Urovant board of directors before becoming its CEO in March 2020 until June 2023. Before Urovant, Mr. Robinson was President and COO at both Paragon Biosciences and Alkermes, managing operations, product planning, manufacturing and business development. He also held prominent roles at Astellas U.S. and Schering-Plough Pharmaceuticals, focusing on commercial operations and sales.

Board Member

Dr. Wen is an emergency physician and has served as a professor of health policy and management at the George Washington University School of Public Health since September 2019. She has been a contributing columnist for The Washington Post since June 2020, writing on health policy and public health, and an on-air commentator for CNN as a medical analyst since August 2020. From January 2015 to October 2018, she was the health commissioner for the city of Baltimore, where she led the nation's oldest continuously operating health department to combat the opioid epidemic and improve maternal and child health. From 2013 to 2015, Dr. Wen served as director of patient-centered care research in the department of emergency medicine at George Washington University and authored a critically acclaimed book on patient advocacy. She is currently on the board of the Bipartisan Policy Center, Baltimore Community Foundation, and National Committee on U.S.-China Relations, and chairs the advisory board of the Behavioral Health Group. She has also been a global health fellow at the World Health Organization, a consultant with the China Medical Board, and a nonresident senior fellow at the Brookings Institution. Dr. Wen also served as the President of Planned Parenthood from 2018 through 2019.

Board Member

Dan Wildman is a seasoned executive with over 40 years of experience in the Medical Device Industry. He is current Chairman of the Board of Progenerative Medical, Inc., a pre-commercial company translating clinically proven reduced pressure technology into medical treatments for orthopedic surgeries. He also serves as a Strategic Adviser for several medical device/pharmaceutical companies.

We are dedicated to
helping patients get the treatments that they deserve